WLA's pipeline from Agouron from a Reuters story:
Warner-Lambert, which has said previously it was financially able to
grow by buying other drug makers or products, on Monday bought
Agouron Pharmaceuticals Inc. <AGPH.O> -- attracted by the
California firm's pipeline of antiviral and AIDS drugs.
Warner-Lambert said one of the most compelling products acquired
from Agouron was Remune, a killed and altered HIV virus meant to
awaken the immune systems of people infected with the virus that
causes AIDS.
Warner Lambert said Agouron's compounds and its own pipeline
would allow strong earnings growth for years to come.
Wild said he expected at least eight products in the pipeline to each
post eventual sales of $500 million to $1 billion a year, including the
antidepressant Igmesine now in Phase II trials and a nasal spray
developed by Agouron against the rhinovirus that causes the common
cold.
Another three products could have future annual sales of over $1
billion, Wild said, including the anticonvulsant Pregabalin now being
tested against epilepsy, pain and psychiatric disorders such as
anxiety and bipolar disease.
"I think Warner-Lambert has a terrific pipeline, particularly with the
addition of Agouron's compounds. I'd give it a grade of A-minus,"
said Gruntal & Co analyst David Saks.
But Len Jaffe, a drug analyst for Banc of America Securities, said it
was far too early to predict whether most of the drugs in the
Warner-Lambert pipeline would be approved.
"In the short-term, company earnings look like they'll be in great shape
because of Lipitor and Neurontin. Longer term, we still have to
evaluate because some drugs in the pipeline will fall by the wayside,"
he said.
Pfizer Inc <PFE.N>, which co-markets Lipitor, is obliged under
contract terms to allow Warner-Lambert to co-market one or more of
Pfizer's own "significant" drugs in future years. Warner-Lambert told
analysts it expects to learn within the next few months what the Pfizer
product or products would be.
moneynet.com@NEWS-P1&Index=0&HeadlineURL=../News/NewsHeadlines.asp&DISABLE_FORM=&NAVSVC=News\Company |
